jama tirzepatide In patients with cardiometabolic #HFpEF, #semaglutide and #tirzepatide reduced the risk of hospitalization for heart failure or all-cause mortality vs sitagliptin, but offered no additional benefit over semaglutide. #ESCCongress #WCCardio JAMA: Semaglutide and Tirzepatide in

Given these single-agent efficacy profiles and the lack of comparative benefit data for combinations, current clinical consensus favors optimizing GLP-1 dosing before considering additional agents

The formation of ice crystals anywhere in the solution can disrupt the peptide bonds of the entire batch

GLP-1 also reduces appetite and slows the passage of food out of the stomach, making you less hungry after a big meal

Were highly experienced medical providers, which allows us to offer more informed care compared to many other med spas that solely focus on cosmetic weight loss

Intensive glycemic control and macrovascular, microvascular, hypoglycemia complications and mortality in older (age 60 years) or frail adults with type 2 diabetes: a systematic review and meta-analysis from randomized controlled trial and observation studies

By starting with a low dose, you give your digestive system time to adjust to this change